PMID- 7512681
OWN - NLM
STAT- MEDLINE
DCOM- 19940519
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 343
IP  - 8905
DP  - 1994 Apr 30
TI  - Diagnosis of growth-hormone deficiency in adults.
PG  - 1064-8
AB  - There is no consensus as to the most appropriate method of diagnosing 
      growth-hormone (GH) deficiency in adults. We have evaluated the relative 
      diagnostic merits of measuring peak GH response to insulin-induced hypoglycaemia 
      (insulin tolerance test), mean 24 h GH concentration derived from 20 min 
      sampling, serum insulin-like growth factor I (IGF-I) concentrations, and serum 
      IGF binding protein 3 (IGFBP-3) concentrations. These tests were undertaken in 23 
      patients considered GH deficient from extensive organic pituitary disease, and in 
      35 sex-matched normal subjects of similar age and body-mass index. Hypopituitary 
      subjects had significantly lower stimulated peak GH, mean 24 h GH, IGF-I, and 
      IGFBP-3 concentrations than normal subjects. The ranges of stimulated peak GH 
      responses were clearly separated between the hypopituitary (< 0.2-3.1 ng/mL) and 
      normal (5.3-42.5 ng/mL) groups, but mean 24 h GH, IGF-I, and IGFBP-3 
      concentrations overlapped. Mean 24 h GH concentrations were below assay 
      sensitivity in 80% of hypopituitary subjects and 16% of normal subjects. 70% and 
      72%, respectively, of the IGF-I and IGFBP-3 values in hypopituitary subjects were 
      within the range for normal subjects. We conclude that GH deficiency in adults is 
      most reliably identified by stimulatory testing, and that IGF-I and IGFBP-3 are 
      poor diagnostic tests of adult GH deficiency.
FAU - Hoffman, D M
AU  - Hoffman DM
AD  - Garvan Institute of Medical Research, St Vincent's Hospital, Sydney, NSW, 
      Australia.
FAU - O'Sullivan, A J
AU  - O'Sullivan AJ
FAU - Baxter, R C
AU  - Baxter RC
FAU - Ho, K K
AU  - Ho KK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Carrier Proteins)
RN  - 0 (Insulin)
RN  - 0 (Insulin-Like Growth Factor Binding Proteins)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 9002-72-6 (Growth Hormone)
SB  - IM
EIN - Lancet 1994 Jul 16;344(8916):206
CIN - Lancet. 1994 Jun 25;343(8913):1645-6. PMID: 7516461
CIN - Lancet. 1994 Apr 30;343(8905):1050-1. PMID: 7909093
CIN - Lancet. 1994 Jun 4;343(8910):1429. PMID: 7910904
CIN - Lancet. 1994 Jun 25;343(8913):1646. PMID: 7911955
CIN - Lancet. 1994 Jun 25;343(8913):1646. PMID: 7911956
CIN - Lancet. 1994 Aug 13;344(8920):483. PMID: 7914599
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Body Mass Index
MH  - Carrier Proteins/blood
MH  - Female
MH  - Glucose Tolerance Test
MH  - Growth Disorders/diagnosis
MH  - Growth Hormone/*blood/*deficiency
MH  - Humans
MH  - Hypopituitarism/*blood
MH  - Insulin/administration & dosage
MH  - Insulin-Like Growth Factor Binding Proteins
MH  - Insulin-Like Growth Factor I/analysis
MH  - Male
MH  - Middle Aged
MH  - Radioimmunoassay
MH  - Sensitivity and Specificity
EDAT- 1994/04/30 00:00
MHDA- 1994/04/30 00:01
CRDT- 1994/04/30 00:00
PHST- 1994/04/30 00:00 [pubmed]
PHST- 1994/04/30 00:01 [medline]
PHST- 1994/04/30 00:00 [entrez]
AID - S0140-6736(94)90181-3 [pii]
AID - 10.1016/s0140-6736(94)90181-3 [doi]
PST - ppublish
SO  - Lancet. 1994 Apr 30;343(8905):1064-8. doi: 10.1016/s0140-6736(94)90181-3.